Avenue Therapeutics, Inc. (ATXI) financial statements (2022 and earlier)

Company profile

Business Address 2 GANSEVOORT STREET
NEW YORK, NY 10014
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3,7633,1328,7452,67121,782
Cash and cash equivalents3,7633,1328,7452,67111,782
Short-term investments    10,000
Receivables90    
Deferred costs   1,702 
Other undisclosed current assets107    
Total current assets:3,9603,1328,7454,37321,782
Noncurrent Assets
Other undisclosed assets 113170152388
TOTAL ASSETS:3,9603,2458,9154,52522,170
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4518571,1014,6692,737
Accounts payable3041433543,0891,545
Accrued liabilities1236912701,117977
Employee-related liabilities2423477463215
Other undisclosed current liabilities58291,01448753
Total current liabilities:5098862,1155,1562,790
Noncurrent Liabilities
Total liabilities:5098862,1155,1562,790
Stockholders' equity
Stockholders' equity attributable to parent, including:3,4512,3596,800(631)19,380
Common stock22211
Additional paid in capital80,44875,62574,91541,57738,937
Accumulated deficit(76,999)(73,268)(68,117)(42,209)(20,661)
Other undisclosed stockholders' equity attributable to parent    1,103
Total stockholders' equity:3,4512,3596,800(631)19,380
TOTAL LIABILITIES AND EQUITY:3,9603,2458,9154,52522,170

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Operating expenses(3,738)(5,213)(25,265)(21,816)(10,318)
Other undisclosed operating loss  (1,000) (1,103)
Operating loss:(3,738)(5,213)(26,265)(21,816)(11,421)
Nonoperating income76235726888
Investment income, nonoperating7623579388
Other nonoperating income   175 
Interest and debt expense    (294)
Net loss:(3,731)(5,151)(25,908)(21,548)(11,627)
Other undisclosed net loss attributable to parent    (631)
Net loss available to common stockholders, diluted:(3,731)(5,151)(25,908)(21,548)(12,258)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(3,731)(5,151)(25,908)(21,548)(11,627)
Comprehensive loss, net of tax, attributable to parent:(3,731)(5,151)(25,908)(21,548)(11,627)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: